Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Streamline of expert assessment process for Nitrosamines Project

A Swiss pharmaceutical company sought assistance in streamlining their expert assessment process for a Nitrosamines Project to address regulatory requirements efficiently. They needed support in coordinating cross-functional teams, managing complex data, and ensuring consistent evaluations across products. The focus was on establishing clear workflows, enhancing communication, and creating standardized tools to improve the accuracy and speed of the assessment process while maintaining compliance.

Challenges Faced

A detailed GAP analysis in Quality Management Systems is essential for identifying process deficiencies effectively.
  • Complexity of Expert Assessment: The most prominent issues included managing a high volume of complex data inputs, ensuring consistent interpretation of evolving regulatory guidelines, and coordinating among multiple internal teams
  • Document Volume: Constraints on available expertise and resources, along with integrating findings into existing workflows, were shown as significant hurdles.
  • Documentation: Experts faced difficulties due to the absence of master data and a centralized documentation repository. Without a single, consolidated source of information, the process of evaluating drug products became time-consuming. Multiple disconnected data sets, varying formats, and unclear points of reference led to inconsistencies, inefficiencies, and potential risk of errors in their assessments.

Zamann Pharma Support’s Approach

  • Project Initialization: A clearly defined workflow was needed to standardize the evaluation steps for expert assessments in the Nitrosamines Project. This involved outlining the sequence of tasks, assigning responsibilities, and creating formalized procedures for reviewing data and making decisions.
  • Expert Evaluation: Establishing regular checkpoints, consistent documentation methods, and clear communication channels ensured that the evaluation process remained organized, efficient, and aligned with regulatory expectations.
  • Expert Assessments Documentation: Templates needed to be carefully structured to include all relevant information about each drug product, ensuring consistency and completeness in expert assessments. These templates captured essential details such as product composition, manufacturing history, and potential nitrosamine risk factors. By standardizing formats and content, the templates supported more systematic evaluations, allowed for easier data comparison, and reduced the likelihood of errors or omissions. This approach simplified the expert assessment process and facilitated timely, accurate decision-making.
  • Communication: Priority drug products were clearly identified and communicated to experts through established channels and documentation. This involved sharing regularly updated lists, criteria for prioritization, and any underlying regulatory deadlines. By providing transparent guidelines and consistent communication, the experts could focus their efforts efficiently, ensuring that critical assessments received attention first and contributing to timely, informed decision-making.
  • Support for Implementation: Workstreams were trained through a structured program designed by subject-matter experts, covering each step of the defined process. Clear guidelines, hands-on demonstrations, and practical examples helped participants understand their roles and responsibilities. This ensured everyone involved had the necessary knowledge and skills, leading to consistent, efficient execution and alignment with established standards.

Results Achieved

  • Regulatory Compliance: By defining a clear, structured expert assessment process, regulatory requirements were fully integrated into each phase of evaluation. Detailed guidelines ensured that all stakeholders followed approved protocols, used validated methods, and maintained proper documentation.
  • Improved Documentation: By establishing a well-defined expert assessment process, the quality and consistency of evaluations significantly improved. Clear criteria, standardized templates, and structured workflows ensured that experts could focus on meaningful analysis rather than administrative hurdles. This led to more accurate, timely, and reliable assessments, ultimately enhancing decision-making and supporting better outcomes.
Laboratory
Pharmaceutical quality team reviewing nitrosamines risk assessment documentation aligned with ICH M7 and current regulatory compliance requirements
Services

Nitrosamines Regulatory Compliance

We assist pharmaceutical teams in assessing and managing nitrosamines risks by aligning processes with ICH M7 requirements and current regulatory expectations.

Read More

Contact Us

Need help? Don't hesitate to get in touch
Zamann pharma support is committed to protecting and respecting your privacy, and we’ll use your personal information to administer your account and to provide the products and services you requested from us.

FAQ

1. How do regulatory teams ensure consistency when multiple experts evaluate nitrosamine risk across different drug products?

Teams enforce a standardized assessment framework that defines step-by-step evaluation criteria for all experts. First, they align interpretation rules for regulatory guidance such as EMA and ICH expectations. Then, they apply unified decision templates to every product review. As a result, expert judgments remain consistent, even when multiple reviewers handle high-volume datasets across different therapeutic products.

2. What is the most effective way to reduce errors caused by fragmented data during expert evaluation of nitrosamine risks?

The most effective method is to centralize all product-related data into a structured master repository before assessment begins. In addition, teams integrate manufacturing history, composition data, and risk factors into standardized formats. Therefore, experts eliminate ambiguity caused by scattered files and inconsistent datasets, which significantly reduces the risk of incomplete or incorrect evaluations.

3. How can pharmaceutical companies speed up expert assessment cycles without compromising regulatory compliance or documentation quality?

Companies accelerate assessment cycles by introducing predefined workflows, prioritized product lists, and structured documentation templates. Moreover, they implement regular review checkpoints to ensure alignment with compliance requirements. Consequently, experts focus on decision-making rather than administrative tasks, which improves turnaround time while maintaining full audit readiness and regulatory integrity.